LOS ANGELES, Oct. 27, 2020 (GLOBE NEWSWIRE) -- via InvestorWire – InvestorBrandNetwork (“IBN”), a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The Stock2Me Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels.
The Stock2Me Podcast features a fascinating array of companies and individuals, many of whom are actively revolutionizing age-old business practices within their respective markets. Stock2Me’s latest podcast features Shawn Singh, CEO of VistaGen Therapeutics Inc. (NASDAQ: VTGN).
“Throughout the many years I’ve been in the [biopharma] space, I really haven’t been satisfied with the treatment alternatives that have been available to people all around the world who are suffering from mental illness, especially anxiety and depression,” Singh stated during the interview. “VistaGen provides, I think, an opportunity for tremendous excitement, given what we’re working on in our pipeline. We have three drug candidates focused on trying to go beyond the current standard of care for anxiety, depression and other CNS, or central nervous system, disorders.”
VistaGen’s lead drug candidate, PH94B, is a first-in-class neuroactive nasal spray that’s currently being developed as an acute treatment for anxiety in adults with Social Anxiety Disorder (SAD). Fast-acting (10-15 minutes), non-systemic and non-sedating in Phase 2 clinical studies, PH94B has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA), positioning it to potentially become the first FDA-approved fast-acting acute treatment for adults with SAD, if planned Phase 3 studies are successful.
The company’s development pipeline also includes PH10, an investigational synthetic neuroactive nasal spray being initially developed as a potential fast-acting, non-sedating, non-addictive new generation treatment of major depressive disorder (MDD), and AV-101, an oral prodrug of 7-chloro-kynurenic acid (7-Cl-KYNA) with potential to serve as an innovative treatment for MDD and multiple neurological indications where current therapies are unsatisfactory.
“What’s exciting about all of these and where we see some game-changing potential in the landscape is the way they work and how fundamentally different we think each of them is from current treatment alternatives,” Singh continued. “The way a drug works and the way it works in the brain for a neuropsychiatric indication is critical. ... We’ve got, I think, an opportunity, based on the drug development programs we’ve got moving, to really swing the paradigm into a different direction where patients can learn faster whether a drug is going to deliver a benefit, and they’re not going to have to, during that period, worry as much about the types of side effects and safety concerns that are associated with current therapies.”
Join InvestorBrandNetwork’s Stuart Smith and VistaGen’s Shawn Singh in exploring how VistaGen is working to redefine the standard of care for people suffering from anxiety, depression and other CNS disorders through the continued advancement of its promising development pipeline.
To hear the whole episode and subscribe for future episodes, visit: https://podcast.stock2me.com
The latest installment of The Stock2Me Podcast continues to reinforce InvestorBrandNetwork’s commitment to the expansion of its robust network of brands, client partners, followers and the growing IBN Podcast Series. For more than 15 years, IBN has leveraged this commitment to provide unparalleled distribution and corporate messaging solutions to 500+ public and private companies.
To learn more about IBN’s achievements and milestones via a visual timeline, visit: https://IBN.fm/TimeLine
The InvestorBrandNetwork (“IBN”) consists of financial brands introduced to the investment public over the course of 15+ years. With IBN, we have amassed a collective audience of millions of social media followers. These distinctive investor brands aim to fulfill the unique needs of a growing base of client-partners. IBN will continue to expand our branded network of highly influential properties, leveraging the knowledge and energy of specialized teams of experts to serve our increasingly diversified list of clients.
Through NetworkNewsWire (“NNW”) and its affiliate brands, IBN provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) full-scale distribution to a growing social media audience; (5) a full array of corporate communications solutions; and (6) a total news coverage solution.
For more information about IBN, visit https://www.InvestorBrandNetwork.com.
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company's SEC filings. These risks and uncertainties could cause the company's actual results to differ materially from those indicated in the forward-looking statements.